- Stocks
- Pharma & Healthcare
- Zydus Lifesciences
Zydus Lifesciences share price
NSE: ZYDUSLIFEPharma & HealthcareDrug Manufacturers - Specialty & Generic
Zydus Lifesciences at a glance
Zydus Lifesciences (NSE: ZYDUSLIFE) closed at ₹1,115.50 on 21 Oct 2026, up 0.36% on the day. With a market capitalisation of ₹1,11,272 Cr, it ranks 89th by market cap among the 4,183 NSE companies Pivot tracks (a large-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 22.3× trailing earnings, against a return on equity of 18.6% in FY26. Over the past year the share price has risen 12.2%. Its 52-week range is ₹835.50 (2 Apr 2026) to ₹1,232.10 (29 Sep 2026); the last close is 9.5% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹7,434 Cr (+18.2% year on year) and net profit ₹1,341 Cr (+7.4%), on a consolidated basis. Promoters held 75.01% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,11,272 CrRank 89 on NSE
- P/E (trailing)
- 22.3×
- Price to book
- 3.23×FY26
- EPS (TTM)
- ₹50.10to Q4 FY26
- ROE
- 18.6%FY26
- ROCE
- 20.6%FY26
- Debt to equity
- 0.43FY26
- Net profit margin
- 18.5%FY26
- Book value / share
- ₹269.50FY26
- Dividend payout
- 22.0%FY26
- 52-week high
- ₹1,232.1029 Sep 2026
- 52-week low
- ₹835.502 Apr 2026
- 1-year return
- +12.2%
- RSI (14-day)
- 43.3
Returns to 21 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.36% | −1.2% | −3.7% | −2.5% | +12.2% |
Zydus Lifesciences quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹6,047 Cr | ₹5,114 Cr | ₹5,124 Cr | ₹6,290 Cr | ₹6,467 Cr | ₹6,038 Cr | ₹6,780 Cr | ₹7,434 Cr |
| Revenue YoY | +17.6% | +17.0% | +13.7% | +17.2% | +7.0% | +18.1% | +32.3% | +18.2% |
| Net profit | ₹1,464 Cr | ₹898 Cr | ₹1,004 Cr | ₹1,249 Cr | ₹1,487 Cr | ₹1,233 Cr | ₹965 Cr | ₹1,341 Cr |
| Net profit YoY | +31.6% | +15.2% | +36.9% | +1.6% | +1.6% | +37.3% | −3.9% | +7.4% |
| Net margin | 24.2% | 17.6% | 19.6% | 19.9% | 23.0% | 20.4% | 14.2% | 18.0% |
| EPS | ₹14.11 | ₹9.06 | ₹10.17 | ₹11.64 | ₹14.58 | ₹12.51 | ₹10.36 | ₹12.65 |
Zydus Lifesciences financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹14,404 Cr | ₹15,265 Cr | ₹17,237 Cr | ₹19,547 Cr | ₹23,242 Cr | — |
| Operating profit | ₹2,604 Cr | ₹2,725 Cr | ₹3,194 Cr | ₹4,823 Cr | ₹6,246 Cr | — |
| Net profit | ₹2,138 Cr | ₹4,572 Cr | ₹1,997 Cr | ₹3,854 Cr | ₹4,615 Cr | — |
| EPS (₹) | ₹21.00 | ₹44.00 | ₹19.00 | ₹38.00 | ₹45.00 | — |
| Cash from operations | ₹3,294 Cr | ₹2,104 Cr | ₹2,689 Cr | ₹3,228 Cr | ₹6,777 Cr | — |
| Total debt | ₹610 Cr | ₹362 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹3,188 Cr |
| Shareholders' equity | ₹12,992 Cr | ₹17,000 Cr | ₹17,516 Cr | ₹19,830 Cr | ₹23,953 Cr | ₹27,111 Cr |
Zydus Lifesciences shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 18 Jun 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 74.99% | 74.99% | 75.00% | 75.00% | 75.01% | 75.01% |
| Foreign institutions | 7.13% | 7.34% | 7.06% | 6.95% | 6.89% | 6.88% |
| Domestic institutions | 11.13% | 10.86% | 11.09% | 11.20% | 11.19% | 11.27% |
| Non-institutions | 6.74% | 6.80% | 6.85% | 6.86% | 6.90% | 6.83% |
Zydus Lifesciences vs peers
The listed Pharma & Healthcare companies nearest to Zydus Lifesciences by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ZYDUSLIFEZydus Lifesciences | ₹1,115.50 | +0.36% | +12.2% | ₹1,11,272 Cr | 22.3 | 18.6% |
| LAURUSLABSLaurus Labs | ₹2,053.00 | −0.43% | +134.9% | ₹1,10,913 Cr | 124.3 | 8.0% |
| APOLLOHOSPApollo Hospitals Enterprise | ₹7,702.50 | +0.10% | +0.3% | ₹1,10,750 Cr | 57 | 20.5% |
| CIPLACipla | ₹1,326.60 | +0.20% | −15.0% | ₹1,07,169 Cr | 27.6 | 11.3% |
| DRREDDYDr. Reddy's Laboratories | ₹1,244.70 | +0.28% | −1.4% | ₹1,03,892 Cr | 25 | 11.1% |
| MANKINDMankind Pharma | ₹2,254.80 | +0.17% | −7.4% | ₹93,122 Cr | 48.8 | 11.7% |
| AUROPHARMAAurobindo Pharma | ₹1,616.70 | −0.02% | +42.6% | ₹93,021 Cr | 26.8 | 9.2% |
Ask anything about Zydus Lifesciences
Pivot answers on the live chart with evidence you can check, and tests strategies against ZYDUSLIFE's own history. Try: “Why has ZYDUSLIFE moved over the last three months?” · “Backtest a 50-day moving-average crossover on ZYDUSLIFE over five years” · “Compare ZYDUSLIFE with LAURUSLABS on margins and valuation”
Frequently asked questions about Zydus Lifesciences
What is the share price of Zydus Lifesciences today?
Zydus Lifesciences (NSE: ZYDUSLIFE) last closed at ₹1,115.50 on 21 Oct 2026. Its 52-week high is ₹1,232.10 and its 52-week low is ₹835.50.
What is the market cap of Zydus Lifesciences?
Zydus Lifesciences' market capitalisation is ₹1,11,272 Cr (₹1.11 lakh Cr) at the 21 Oct 2026 close, ranking 89th among the NSE companies Pivot tracks.
What is the P/E ratio of Zydus Lifesciences?
Zydus Lifesciences trades at a trailing P/E of 22.3. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 48.8.
What is the ROE and ROCE of Zydus Lifesciences?
Return on equity was 18.6% in FY26 and return on capital employed was 20.6% in FY26 (consolidated figures).
Is Zydus Lifesciences a debt-free company?
No. Zydus Lifesciences' debt-to-equity ratio was 0.43 in FY26, with total debt of ₹3,188 Cr.
What were Zydus Lifesciences' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Zydus Lifesciences reported revenue of ₹7,434 Cr, +18.2% year on year, and net profit of ₹1,341 Cr, +7.4% year on year.
How has Zydus Lifesciences stock performed over the last year?
Zydus Lifesciences' share price has risen 12.2% over the past year, −2.5% over three months and −3.7% over one month, to the 21 Oct 2026 close.
What is the shareholding pattern of Zydus Lifesciences?
As of 30 Jun 2026: promoters 75.01%, foreign institutions 6.88%, domestic institutions 11.27%, non-institutions 6.83%.
Who are Zydus Lifesciences' competitors?
The listed Pharma & Healthcare companies closest to Zydus Lifesciences by market cap are Laurus Labs, Apollo Hospitals Enterprise, Cipla, Dr. Reddy's Laboratories, Mankind Pharma and Aurobindo Pharma.
Is Zydus Lifesciences a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Zydus Lifesciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ZYDUSLIFE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026 (returns and ratios at the 21 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with Z · all NSE stocks · this page as text